Volodymir Kovalenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Volodymir Kovalenko has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrii V. Kalashnikov
State University “Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
1 shared publication - Inna V. Gogunska
STATE INSTITUTION “INSTITUTE OF OTOLARYNGOLOGY NAMED AFTER PROF. O.S. KOLOMIYCHENKO OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE”, KYIV, UKRAINE
1 shared publication - Mykola M. Veliky
Palladin Institute of Biochemistry, The National Academy of Sciences of Ukraine, 02000 Kyiv, Ukraine
1 shared publication - Mykola Tronko
V.P. Komisarenko Institute of Endocrinology and Metabolism: Kyiv, UA
1 shared publication - Nataliia Grygorieva
State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
1 shared publication - Ninel V. Dedukh
D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults
Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.
Open AccessUkrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults
Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.